Funding and research


Why research?

Our goal is to combat EHE through the discovery of drug regimens and treatments that will allow us to manage and control EHE. To achieve this, we must first understand this rare cancer. We know that it can present in either an indolent (slow-growing) or an aggressive phase, but we do not yet know what dictates which phase is present, nor the trigger(s) that cause the indolent form to became aggressive, nor the reasons why it is often aggressive in children and young adults. We do not yet fully understand what causes EHE, what factors may lead to a person being predisposed to EHE, nor how it spreads within the body; nor do we understand the natural history of this cancer.


Current research

The EHE Rare Cancer Charity (UK) is therefore dedicated to promoting and supporting the research necessary to find the answers to these questions. Currently the only coordinated research programme into EHE is that led by Dr Brian Rubin from his research laboratories in the Cleveland Clinic in the USA, in collaboration with other American and international research facilities and cancer clinics. Please go to our RESEARCH section for more information about Dr Rubin's research programme, as well as other EHE research we are promoting. A summary of our EHE GROUP RESEARCH  AND FUNDRAISING STRATEGY 2017 can be found in the RESOURCES section of this site. In addition, a broader overview of the research and associated fundraising objectives of the EHE Group can be found in our FUNDRAISING AND RESEARCH OBJECTIVES information sheet which can also be found in the RESOURCES section of this website.


Our support

We support the research programme in two important ways. First, our members can provide important data relating to themselves and their cancer. This is the type of patient data that typically is not available for rare cancers, and can provide critical information to medical and research specialists working with EHE. Second, research cannot progress if it is not funded. There is almost no government funding for research into rare cancers. Established charities and foundations also provide extremely limited funding at the early stages of such research. We will therefore continue to strive to raise from our members and from external sources the funds needed to allow EHE research to progress and lead to the understanding we need to combat this disease.